These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

427 related items for PubMed ID: 23562987

  • 41. Real-life experience with switching TNF-α inhibitors in ankylosing spondylitis.
    Gulyas K, Bodnar N, Nagy Z, Szamosi S, Horvath A, Vancsa A, Vegh E, Szabo Z, Szucs G, Szekanecz Z, Szanto S.
    Eur J Health Econ; 2014 May; 15 Suppl 1():S93-100. PubMed ID: 24832840
    [Abstract] [Full Text] [Related]

  • 42. Observational study of switching anti-TNF agents in ankylosing spondylitis and psoriatic arthritis versus rheumatoid arthritis.
    Haberhauer G, Strehblow C, Fasching P.
    Wien Med Wochenschr; 2010 May; 160(9-10):220-4. PubMed ID: 20632149
    [Abstract] [Full Text] [Related]

  • 43. Tumor necrosis factor inhibitors in psoriatic arthritis.
    Mantravadi S, Ogdie A, Kraft WK.
    Expert Rev Clin Pharmacol; 2017 Aug; 10(8):899-910. PubMed ID: 28490202
    [Abstract] [Full Text] [Related]

  • 44. Matching-adjusted indirect comparison of adalimumab vs etanercept and infliximab for the treatment of psoriatic arthritis.
    Kirson NY, Rao S, Birnbaum HG, Kantor E, Wei RS, Cifaldi M.
    J Med Econ; 2013 Aug; 16(4):479-89. PubMed ID: 23339434
    [Abstract] [Full Text] [Related]

  • 45. Effectiveness and treatment retention of TNF inhibitors when used as monotherapy versus comedication with csDMARDs in 15 332 patients with psoriatic arthritis. Data from the EuroSpA collaboration.
    Lindström U, Di Giuseppe D, Delcoigne B, Glintborg B, Möller B, Ciurea A, Pombo-Suarez M, Sanchez-Piedra C, Eklund K, Relas H, Gudbjornsson B, Love TJ, Jones GT, Codreanu C, Ionescu R, Nekvindova L, Závada J, Atas N, Yolbas S, Fagerli KM, Michelsen B, Rotar Ž, Tomšič M, Iannone F, Santos MJ, Avila-Ribeiro P, Ørnbjerg LM, Østergaard M, Jacobsson LT, Askling J, Nissen MJ.
    Ann Rheum Dis; 2021 Nov; 80(11):1410-1418. PubMed ID: 34083206
    [Abstract] [Full Text] [Related]

  • 46. Tumour necrosis factor α blockers are more effective than methotrexate in the inhibition of radiographic joint damage progression among patients with psoriatic arthritis.
    Eder L, Thavaneswaran A, Chandran V, Gladman DD.
    Ann Rheum Dis; 2014 Jun; 73(6):1007-11. PubMed ID: 23619157
    [Abstract] [Full Text] [Related]

  • 47. Calprotectin and TNF trough serum levels identify power Doppler ultrasound synovitis in rheumatoid arthritis and psoriatic arthritis patients in remission or with low disease activity.
    Inciarte-Mundo J, Ramirez J, Hernández MV, Ruiz-Esquide V, Cuervo A, Cabrera-Villalba SR, Pascal M, Yagüe J, Cañete JD, Sanmarti R.
    Arthritis Res Ther; 2016 Jul 08; 18(1):160. PubMed ID: 27391315
    [Abstract] [Full Text] [Related]

  • 48. Evidence for differential acquired drug resistance to anti-tumour necrosis factor agents in rheumatoid arthritis.
    Finckh A, Simard JF, Gabay C, Guerne PA, SCQM physicians.
    Ann Rheum Dis; 2006 Jun 08; 65(6):746-52. PubMed ID: 16339288
    [Abstract] [Full Text] [Related]

  • 49. Comparison of effectiveness and safety of infliximab, etanercept, and adalimumab in psoriatic arthritis patients who experienced an inadequate response to previous disease-modifying antirheumatic drugs.
    Atteno M, Peluso R, Costa L, Padula S, Iervolino S, Caso F, Sanduzzi A, Lubrano E, Del Puente A, Scarpa R.
    Clin Rheumatol; 2010 Apr 08; 29(4):399-403. PubMed ID: 20066450
    [Abstract] [Full Text] [Related]

  • 50. Effects of ustekinumab versus tumor necrosis factor inhibition on enthesitis: Results from the enthesial clearance in psoriatic arthritis (ECLIPSA) study.
    Araujo EG, Englbrecht M, Hoepken S, Finzel S, Kampylafka E, Kleyer A, Bayat S, Schoenau V, Hueber A, Rech J, Schett G.
    Semin Arthritis Rheum; 2019 Feb 08; 48(4):632-637. PubMed ID: 30037432
    [Abstract] [Full Text] [Related]

  • 51. Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study.
    Hyrich KL, Lunt M, Watson KD, Symmons DP, Silman AJ, British Society for Rheumatology Biologics Register.
    Arthritis Rheum; 2007 Jan 08; 56(1):13-20. PubMed ID: 17195186
    [Abstract] [Full Text] [Related]

  • 52. Treatment patterns in the first year after initiating tumor necrosis factor blockers in real-world settings.
    Bonafede M, Fox KM, Watson C, Princic N, Gandra SR.
    Adv Ther; 2012 Aug 08; 29(8):664-74. PubMed ID: 22886712
    [Abstract] [Full Text] [Related]

  • 53. Long-term work disability in patients with psoriatic arthritis treated with anti-tumour necrosis factor: a population-based regional Swedish cohort study.
    Kristensen LE, Englund M, Neovius M, Askling J, Jacobsson LT, Petersson IF.
    Ann Rheum Dis; 2013 Oct 08; 72(10):1675-9. PubMed ID: 23148309
    [Abstract] [Full Text] [Related]

  • 54. The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: a systematic review and meta-analysis of randomized controlled trials.
    Dommasch ED, Abuabara K, Shin DB, Nguyen J, Troxel AB, Gelfand JM.
    J Am Acad Dermatol; 2011 Jun 08; 64(6):1035-50. PubMed ID: 21315483
    [Abstract] [Full Text] [Related]

  • 55. Clinical Outcomes and Biologic Costs of Switching Between Tumor Necrosis Factor Inhibitors in US Veterans with Rheumatoid Arthritis.
    Cannon GW, DuVall SL, Haroldsen CL, Caplan L, Curtis JR, Michaud K, Mikuls TR, Reimold A, Collier DH, Joseph GJ, Harrison DJ, Sauer BC.
    Adv Ther; 2016 Aug 08; 33(8):1347-59. PubMed ID: 27352377
    [Abstract] [Full Text] [Related]

  • 56. The effectiveness of a real life dose reduction strategy for tumour necrosis factor inhibitors in ankylosing spondylitis and psoriatic arthritis.
    Fong W, Holroyd C, Davidson B, Armstrong R, Harvey N, Dennison E, Cooper C, Edwards CJ.
    Rheumatology (Oxford); 2016 Oct 08; 55(10):1837-42. PubMed ID: 27354684
    [Abstract] [Full Text] [Related]

  • 57. Real-world evaluation of TNF-inhibitor utilization in rheumatoid arthritis.
    Harnett J, Wiederkehr D, Gerber R, Gruben D, Koenig A, Bourret J.
    J Med Econ; 2016 Oct 08; 19(2):91-102. PubMed ID: 26401963
    [Abstract] [Full Text] [Related]

  • 58. Direct and indirect comparison of the efficacy and safety of adalimumab, etanercept, infliximab and golimumab in psoriatic arthritis.
    Fénix-Caballero S, Alegre-del Rey EJ, Castaño-Lara R, Puigventós-Latorre F, Borrero-Rubio JM, López-Vallejo JF.
    J Clin Pharm Ther; 2013 Aug 08; 38(4):286-93. PubMed ID: 23590560
    [Abstract] [Full Text] [Related]

  • 59. Switching biologics in the treatment of psoriatic arthritis.
    Merola JF, Lockshin B, Mody EA.
    Semin Arthritis Rheum; 2017 Aug 08; 47(1):29-37. PubMed ID: 28363434
    [Abstract] [Full Text] [Related]

  • 60. Tumour necrosis factor inhibitor survival and predictors of response in axial spondyloarthritis-findings from a United Kingdom cohort.
    Yahya F, Gaffney K, Hamilton L, Lonsdale E, Leeder J, Brooksby A, Cavill C, Berry-Jenkins J, Boyle C, Bond D, Sengupta R, for BRITSpA.
    Rheumatology (Oxford); 2018 Apr 01; 57(4):619-624. PubMed ID: 29272541
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 22.